AU2016290761A1 - Use of modified FC fragments in immunotherapy - Google Patents
Use of modified FC fragments in immunotherapyInfo
- Publication number
- AU2016290761A1 AU2016290761A1 AU2016290761A AU2016290761A AU2016290761A1 AU 2016290761 A1 AU2016290761 A1 AU 2016290761A1 AU 2016290761 A AU2016290761 A AU 2016290761A AU 2016290761 A AU2016290761 A AU 2016290761A AU 2016290761 A1 AU2016290761 A1 AU 2016290761A1
- Authority
- AU
- Australia
- Prior art keywords
- immunotherapy
- fragments
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 title 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2022204834A AU2022204834A1 (en) | 2015-07-06 | 2022-07-06 | Use of modified Fc fragments in immunotherapy |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1556399A FR3038517B1 (en) | 2015-07-06 | 2015-07-06 | USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY |
FR1556399 | 2015-07-06 | ||
PCT/FR2016/051708 WO2017006052A2 (en) | 2015-07-06 | 2016-07-06 | Use of modified fc fragments in immunotherapy |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2022204834A Division AU2022204834A1 (en) | 2015-07-06 | 2022-07-06 | Use of modified Fc fragments in immunotherapy |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2016290761A1 true AU2016290761A1 (en) | 2018-02-22 |
AU2016290761B2 AU2016290761B2 (en) | 2022-04-07 |
Family
ID=54937180
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2016290761A Active AU2016290761B2 (en) | 2015-07-06 | 2016-07-06 | Use of modified FC fragments in immunotherapy |
AU2022204834A Pending AU2022204834A1 (en) | 2015-07-06 | 2022-07-06 | Use of modified Fc fragments in immunotherapy |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2022204834A Pending AU2022204834A1 (en) | 2015-07-06 | 2022-07-06 | Use of modified Fc fragments in immunotherapy |
Country Status (8)
Country | Link |
---|---|
US (1) | US20180355034A1 (en) |
EP (1) | EP3319989A2 (en) |
JP (3) | JP2018524355A (en) |
CN (2) | CN113817049A (en) |
AU (2) | AU2016290761B2 (en) |
CA (1) | CA2990354A1 (en) |
FR (1) | FR3038517B1 (en) |
WO (1) | WO2017006052A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY160298A (en) | 2010-12-30 | 2017-02-28 | Lab Francais Du Fractionnement | Glycols as pathogen inactivating agents |
EP3016729B1 (en) | 2013-07-05 | 2020-03-25 | Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme | Affinity chromatography matrix |
FR3038517B1 (en) * | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY |
AU2018218345A1 (en) * | 2017-02-10 | 2019-08-29 | Genmab B.V. | Polypeptide variants and uses thereof |
FR3064007A1 (en) * | 2017-03-20 | 2018-09-21 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | ANTIBODIES FOR THE TREATMENT OF CANCERS |
FR3075200B1 (en) * | 2017-12-15 | 2022-12-23 | Lab Francais Du Fractionnement | VARIANTS WITH FC FRAGMENT HAVING INCREASED AFFINITY FOR FCRN AND INCREASED AFFINITY FOR AT LEAST ONE FC FRAGMENT RECEIVER |
EP3845558A4 (en) * | 2018-08-29 | 2022-05-18 | Chugai Seiyaku Kabushiki Kaisha | Antibody half-molecule, and method for inhibiting homodimer formation of antibody half-molecule |
CN111825770B (en) * | 2019-04-16 | 2023-06-09 | 成都医学院 | Long-acting interleukin 21-Fc fusion protein and application thereof |
WO2021057726A1 (en) * | 2019-09-23 | 2021-04-01 | 南开大学 | SCREENING OF FC SPECIFICALLY BINDING TO FCγR BY USING MAMMALIAN DISPLAY |
WO2023104128A1 (en) * | 2021-12-09 | 2023-06-15 | 上海宝济药业有限公司 | Fc polypeptide having altered glycosylation modification |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8421551D0 (en) | 1984-08-24 | 1984-09-26 | Ici Plc | Water-soluble dye |
DK2270147T4 (en) | 1999-04-09 | 2020-08-31 | Kyowa Kirin Co Ltd | METHOD OF MONITORING THE ACTIVITY OF IMMUNOLOGICAL FUNCTIONAL MOLECULE |
FR2807767B1 (en) * | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | MONOCLONAL ANTIBODIES ANTI-D |
ES2330330T3 (en) | 2000-06-28 | 2009-12-09 | Glycofi, Inc. | PROCEDURE OF PRODUCTION OF MODIFIED GLUCOPROTEINS. |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
FR2816319B1 (en) | 2000-11-08 | 2004-09-03 | Millegen | USE OF DNA MUTAGEN POLYMERASE FOR THE CREATION OF RANDOM MUTATIONS |
US8093357B2 (en) * | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
WO2003085102A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
US7425449B2 (en) | 2002-04-30 | 2008-09-16 | The Regents Of The University Of California | Site specific Listeria integration vectors and methods for using the same |
US6994292B2 (en) | 2002-10-18 | 2006-02-07 | The Procter & Gamble Company | Dispensing apparatus for web material |
US7355008B2 (en) * | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US20050160485A1 (en) | 2003-03-18 | 2005-07-21 | Kyowa Hakko Kogyo Co., Ltd. | Mouse in which genome is modified |
US20040219143A1 (en) | 2003-04-30 | 2004-11-04 | Bluth Martin Heath | Methods for recombinant immunoglobulin treatment |
WO2005035778A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY USING RNA INHIBITING THE FUNCTION OF α1,6-FUCOSYLTRANSFERASE |
US20060223147A1 (en) | 2004-08-05 | 2006-10-05 | Kyowa Hakko Kogyo Co., Ltd., | Process for producing glycoprotein composition |
CA2608818A1 (en) | 2005-06-03 | 2006-12-14 | Genentech, Inc. | Method of producing antibodies with modified fucosylation level |
DK1945665T3 (en) | 2005-10-21 | 2012-02-06 | Genzyme Corp | Antibody-based therapy agents with elevated ADCC activity |
NZ568433A (en) | 2005-10-21 | 2012-07-27 | Gtc Biotherapeutics Inc | Milk-derived antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use |
US20080206246A1 (en) * | 2006-04-05 | 2008-08-28 | Ravetch Jeffrey V | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
WO2007099988A1 (en) | 2006-02-28 | 2007-09-07 | Kyowa Hakko Kogyo Co., Ltd. | α-1,6-FUCOSYLTRANSFERASE MUTANT AND USE THEREOF |
WO2008151088A2 (en) * | 2007-06-01 | 2008-12-11 | University Of Maryland, Baltimore | Immunoglobulin constant region fc receptor binding agents |
EP2233500A1 (en) * | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
EP2537864B1 (en) * | 2011-06-24 | 2019-08-07 | Laboratoire Français du Fractionnement et des Biotechnologies | Fc variants with reduced effector functions |
TW201326209A (en) * | 2011-09-30 | 2013-07-01 | Chugai Pharmaceutical Co Ltd | Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance |
EP3485909A1 (en) * | 2011-12-19 | 2019-05-22 | The Rockefeller University | Non-sialylated anti-inflammatory polypeptides |
KR102104686B1 (en) * | 2012-01-10 | 2020-04-24 | 바이오젠 엠에이 인코포레이티드 | Enhancement of transport of therapeutic molecules across the blood brain barrier |
EP3470433A1 (en) * | 2012-04-27 | 2019-04-17 | Bioatla, LLC | Modified antibody regions and uses thereof |
CA2903258C (en) * | 2013-03-15 | 2019-11-26 | Amgen Inc. | Heterodimeric bispecific antibodies |
ES2742682T3 (en) * | 2013-12-24 | 2020-02-17 | Argenx Bvba | FCRN antagonists and methods of use |
FR3035879A1 (en) * | 2015-05-07 | 2016-11-11 | Lab Francais Du Fractionnement | MUTANTS FC WITH MODIFIED FUNCTIONAL ACTIVITY |
FR3038517B1 (en) * | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY |
-
2015
- 2015-07-06 FR FR1556399A patent/FR3038517B1/en active Active
-
2016
- 2016-07-06 WO PCT/FR2016/051708 patent/WO2017006052A2/en active Application Filing
- 2016-07-06 CN CN202111105793.XA patent/CN113817049A/en active Pending
- 2016-07-06 JP JP2018500412A patent/JP2018524355A/en not_active Ceased
- 2016-07-06 CN CN201680051282.5A patent/CN108026163B/en active Active
- 2016-07-06 EP EP16747826.2A patent/EP3319989A2/en active Pending
- 2016-07-06 AU AU2016290761A patent/AU2016290761B2/en active Active
- 2016-07-06 CA CA2990354A patent/CA2990354A1/en active Pending
- 2016-07-06 US US15/742,268 patent/US20180355034A1/en active Pending
-
2020
- 2020-12-22 JP JP2020212333A patent/JP7102496B2/en active Active
-
2022
- 2022-07-06 AU AU2022204834A patent/AU2022204834A1/en active Pending
- 2022-07-06 JP JP2022109002A patent/JP2022137152A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3245291A4 (en) | Novel micro-dystrophins and related methods of use | |
AU2016290761A1 (en) | Use of modified FC fragments in immunotherapy | |
EP3177322A4 (en) | Anti-trem2 antibodies and methods of use thereof | |
EP3097122A4 (en) | Binding proteins and methods of use thereof | |
EP3237450A4 (en) | Anti-mertk agonistic antibodies and uses thereof | |
EP3160498A4 (en) | Il-15-based molecules and methods of use thereof | |
EP3125960A4 (en) | Click-crosslinked hydrogels and methods of use | |
EP3218443A4 (en) | Refrigerant compositions and methods of use | |
EP3122761A4 (en) | Engineered light-activated anion channel proteins and methods of use thereof | |
EP3112436A4 (en) | Polishing composition | |
EP3131566A4 (en) | Bi-terminal pegylated integrin-binding peptides and methods of use thereof | |
EP3116911B8 (en) | Anti-mcam antibodies and associated methods of use | |
EP3383917A4 (en) | Novel anti-claudin antibodies and methods of use | |
EP3015526A4 (en) | Halo-olefin composition and use therefor | |
EP3177638A4 (en) | Targeting peptides and methods of use | |
EP3216562A4 (en) | Polishing method and composition for polishing | |
EP3134121A4 (en) | Novel anti-rnf43 antibodies and methods of use | |
EP3226898A4 (en) | Bromodomain inhibitor as adjuvant in cancer immunotherapy | |
EP3215182A4 (en) | Combination immunotherapy | |
EP3394098A4 (en) | Anti-myostatin antibodies and methods of use | |
EP3124570A4 (en) | Polishing composition | |
EP3389705A4 (en) | Listeria-based immunotherapy and methods of use thereof | |
EP3221087A4 (en) | Bonded abrasive articles and methods of manufacture | |
EP3189079A4 (en) | Novel anti-mfi2 antibodies and methods of use | |
EP3107569A4 (en) | Anti-acth antibodies and use thereof |